Results 191 to 200 of about 8,187 (238)
Some of the next articles are maybe not open access.

Cefiderocol: A Siderophore Cephalosporin

Annals of Pharmacotherapy, 2020
Objective: This article reviews the available data on the chemistry, spectrum of activity, pharmacokinetic and pharmacodynamic properties, clinical efficacy, and potential place in therapy of cefiderocol. Data Sources: A literature ...
Rania M. El-Lababidi, John George Rizk
openaire   +2 more sources

Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial.

Lancet. Infectious Diseases (Print)
BACKGROUND Bloodstream infections caused by bacteria with carbapenem resistance are associated with high mortality. Cefiderocol has broad in vitro activity against carbapenem-resistant Gram-negative bacilli. We aimed to assess whether cefiderocol was non-
David L. Paterson   +29 more
semanticscholar   +1 more source

Rapid cefiderocol NP test for detection of cefiderocol susceptibility/resistance in Enterobacterales

Journal of Antimicrobial Chemotherapy, 2022
Abstract Background Cefiderocol is among the latest generation of commercialized antibiotics against a large variety of MDR Gram-negative bacteria including carbapenem-resistant Enterobacterales and non-fermenters such as Pseudomonas aeruginosa and Acinetobacter baumannii.
Patrice Nordmann   +3 more
openaire   +3 more sources

In a Pinch: Cefiderocol for CRAB Infections

Antimicrobial Agents and Chemotherapy, 2022
Carbapenem-resistant Acinetobacter baumannii (CRAB) can cause significant infections with limited treatment options available. Falcone et al. ( https://doi.org/10.1128/aac.02142-21 ) describe a single-center retrospective study comparing clinical outcomes among patients with CRAB infections ...
Sara M. Karaba   +2 more
openaire   +2 more sources

Spanish nation-wide survey of Pseudomonas aeruginosa cefiderocol antimicrobial susceptibility and resistance genomics.

International Journal of Antimicrobial Agents
BACKGROUND Cefiderocol is a new siderophore-cephalosporin showing potent activity against P. aeruginosa, including isolates showing extensively drug resistant (XDR) or difficult to treat resistant (DTR) phenotypes.
M. A. Sastre-Femenia   +10 more
semanticscholar   +1 more source

Cefiderocol: a novel siderophore cephalosporin

Expert Opinion on Investigational Drugs, 2018
The emergence of multidrug-resistant bacterial pathogens has led to a global public health emergency and novel therapeutic options and drug-delivery systems are urgently needed. Cefiderocol is a siderophore cephalosporin antibiotic that has recently been developed to combat a variety of bacterial pathogens, including β-lactam- and carbapenem-resistant ...
Justin J, Choi, Matthew W, McCarthy
openaire   +2 more sources

Cefiderocol

Reactions Weekly, 2023
openaire   +2 more sources

Impact of continuous renal replacement therapy and Cytosorb on cefiderocol pharmacokinetics: “One size does not fit all”

International Journal of Artificial Organs
Cefiderocol, a novel broad-spectrum cephalosporin, exhibits promising efficacy against carbapenem-resistant Gram-negative bacteria via a “Trojan horse” mechanism.
G. Bottari   +11 more
semanticscholar   +1 more source

Cefiderocol

Reactions Weekly, 2020
openaire   +1 more source

Home - About - Disclaimer - Privacy